Study wrapper · #1357
Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort.
Ma J, Ruderman SA, Haidar L, et al. AIDS (London, England). 2026.
DOI: 10.1097/qad.0000000000004544PubMed: 42138385
Editor's note
A large multi-site cohort in a population — people with HIV — largely absent from the semaglutide liver trials, which is what makes this notable. The pre/post design without a comparator group leaves room for regression to the mean, and FIB-4 is a blood-based estimate of fibrosis rather than biopsy or imaging. Still, the dose-response-like pattern by baseline fibrosis severity is consistent with the general-population evidence, including the phase 3 MASH data.
Plain-language abstract
Among 1,850 people with HIV who started semaglutide across 10 US clinical sites, those with moderate-to-advanced liver fibrosis scores saw those scores decline over about seven months on the drug, with the largest improvements in the advanced-fibrosis group.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026